Cyclacel to Present Phase 2 Fadraciclib Data at 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals, Inc., a company dedicated to developing novel cancer treatments, has announced promising initial data from their Phase 2 clinical study of fadraciclib. This study involves twelve patients with advanced solid tumors who were preselected for genetic abnormalities in CDKN2A and/or CDKN2B. These findings will be showcased at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics, scheduled to take place in Barcelona, Spain, from October 23 to 25, 2024.

The poster presentation, titled "Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations," will be available for viewing on October 23. The presentation will provide details about the efficacy and safety of fadraciclib as a monotherapy in this specific patient cohort.

Fadraciclib is designed to inhibit CDK2 and CDK9, enzymes that play crucial roles in cell cycle regulation and transcription. By targeting these enzymes, fadraciclib aims to halt the growth of cancer cells with specific genetic defects. The study focused on patients whose tumors exhibited abnormalities in CDKN2A and CDKN2B, genes associated with cell cycle control.

Cyclacel Pharmaceuticals, headquartered in Berkeley Heights, New Jersey, is committed to advancing cancer treatment through innovative approaches. Alongside fadraciclib, the company is also developing plogosertib, a PLK1 inhibitor, aimed at treating both solid tumors and hematological malignancies. Cyclacel's strategic approach involves building a robust pipeline of novel drug candidates targeting various cancer types.

The recent data from the 065-101 clinical study marks a significant milestone in Cyclacel's journey to bring new therapies to patients in need. By focusing on molecular targets and leveraging genetic insights, the company aims to develop more effective and personalized treatment options for cancer patients.

In addition to its ongoing research efforts, Cyclacel is also focused on establishing a diverse biopharmaceutical business. This involves pursuing both oncology and hematology indications with a range of innovative drug candidates. The company is dedicated to translating scientific breakthroughs into real-world clinical benefits, ultimately improving outcomes for patients with challenging cancers.

The presentation at the AACR-NCI-EORTC Symposium will offer attendees a comprehensive overview of the latest findings from Cyclacel's research. It is an opportunity for the scientific community to engage with new data and discuss the potential implications for future cancer therapies.

As Cyclacel continues to advance its clinical programs, the company remains committed to its mission of developing groundbreaking treatments for cancer patients. The data from the fadraciclib study not only highlights the potential of targeting specific genetic abnormalities but also underscores the importance of personalized medicine in modern oncology.

The insights gained from this study will contribute to the broader understanding of how targeted therapies can be optimized to benefit patients with unique genetic profiles. Cyclacel's ongoing efforts in this area demonstrate the company's dedication to pushing the boundaries of cancer treatment and offering hope to patients worldwide.